AKBA
USDAkebia Therapeutics Inc. Common Stock
Precio en Tiempo Real
Gráfico de Precios
Métricas Clave
Métricas de Mercado
Apertura
$2.100
Máximo
$2.145
Mínimo
$2.070
Volumen
4.47M
Fundamentos de la Empresa
Capitalización de Mercado
563.4M
Industria
Drug Manufacturers - Specialty & Generic
País
United States
Estadísticas de Negociación
Volumen Promedio
4.04M
Bolsa
NCM
Moneda
USD
Rango de 52 Semanas
Noticias Relacionadas
Akebia Therapeutics to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced
HC Wainwright & Co. Maintains Buy on Akebia Therapeutics, Lowers Price Target to $6
HC Wainwright & Co. analyst Matthew Caufield maintains Akebia Therapeutics with a Buy and lowers the price target from $8 to $6.
BTIG Maintains Buy on Akebia Therapeutics, Lowers Price Target to $5
BTIG analyst Julian Harrison maintains Akebia Therapeutics with a Buy and lowers the price target from $10 to $5.
Akebia Therapeutics Provides Update on Vafseo for Non-Dialysis Patients
CAMBRIDGE, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced
Acciones Relacionadas
Mantente Actualizado
Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.